Q-CureMatch is a quantum-assisted drug discovery platform that is used to quickly identify potential drugs. These drugs can be found using quantum algorithms in terms of their binding to a protein, which reduces the time needed for molecular docking experiments. In addition, deep learning helps in improving the accuracy given by statistical models, with the use of elements in personalized medicine, which helps to identify treatment suitable for each individual using their own genomic information. Also, using molecule structure , protein folding information, and response to drugs, itimproves the accuracy of the results. drug discovery, where an understanding of simulatedmolecules at the quantum level is needed . Even though the development of quantum computing machines is at a primitive level, hybrid methods using quantum-classical computing are becoming increasingly higher. The goal of this review paper is to examine current techniques using AI for drug discovery, investigate the latest research in quantum computing applied to molecular modeling, and review hybrid approaches that bridge both technologies. It also focuses on current drawbacks and future enhancements, by laying the ground for the design and implementation of the Q-CureMatch platform. Key Words: Machine learning, quantum computing, molecular docking, drug-discovery, compound screening
Q-CureMatch is a quantum-assisted drug discovery platform that is used to quickly identify potential drugs. These drugs can be found using quantum algorithms in terms of their binding to a protein, which reduces the time needed for molecular docking experiments. In addition, deep learning helps in improving the accuracy given by statistical models, with the use of elements in personalized medicine, which helps to identify treatment suitable for each individual using their own genomic information. Also, using molecule structure , protein folding information, and response to drugs, itimproves the accuracy of the results. drug discovery, where an understanding of simulatedmolecules at the quantum level is needed . Even though the development of quantum computing machines is at a primitive level, hybrid methods using quantum-classical computing are becoming increasingly higher. The goal of this review paper is to examine current techniques using AI for drug discovery, investigate the latest research in quantum computing applied to molecular modeling, and review hybrid approaches that bridge both technologies. It also focuses on current drawbacks and future enhancements, by laying the ground for the design and implementation of the Q-CureMatch platform. Key Words: Machine learning, quantum computing, molecular docking, drug-discovery, compound screening
Research Problem: The traditional methods of drug discovery are time-consuming, costly, and at times ineffective. There is a need for more novel approaches that can enhance the processes of discovering new drugs and developing them into usable products. Objective of the Paper: This paper aims to conduct a review of the literature and find how the application of quantum computing can change the way drugs are discovered and processed in practice. Process of Review: The review process involved a comprehensive examination of the available literature and recent advances in the application of quantum computing to drug discovery. The review encompassed major studies, theories, and case studies related to the subject matter, aiming to identify the current state and potential future directions of the domain. Insights of the Review: 1. Primary Building Blocks: With quantum computing, superposition, entanglement, and other principles can be utilised to enable complex computations to be performed at higher speeds using less time than traditional computers. 2. Quantum modelling: Quantum computers are expected to accurately model the interactions of various molecules, which could result in the identification of viable drug candidates. 3. Drug Discovery Processes: Quantum algorithms are capable of faster processing than traditional methods when it comes to solving optimisation problems, such as protein structure prediction and molecular docking, in drug design. 4. Limitations and Challenges: As great as the promise of quantum computing is, it has its limitations and challenges, including hardware limitations, error rates, and the need for specialised algorithms. 5. Future Developments: The ongoing development of quantum hardware and algorithms is expected to enhance the practical applications of quantum computing in drug discovery, enabling the quicker and more cost-effective creation of new drugs.
Regenerative medicine requires rapid analysis of the best therapeutic molecules capable of interacting with in vivo undifferentiated mass with complex biology and therapeutic properties that are needed to repair and regenerate tissues. The scalability and efficiency of conventional computational solutions and even recent representations with more advanced classical neural networks are limited when it comes to molecular data that are high dimensional. The combination of quantum computing principles and deep learning neural networks provides a potential avenue to speed this process up, by exploiting quantum parallelism, entanglement and superposition in pattern recognition and simulation of molecules through what is known as Quantum Neural Networks (QNNs). The paper describes how to apply QNNs to facilitate the process of target identification, molecular docking, and compound optimization in regenerative medicine in particular. We introduce a conceptual, hybrid quantum classical model to simulate protein-ligand interactions, screen drug candidates and economize on computational costs relative to classical models. The offered solution marks the conceivably quicker performance in molecular screening, better sensitivity in predicting drug-target interactions, and accommodating complex biological data. QNNs by connecting both quantum computing and biomedical innovation can foreseeably lead to much shorter time-to-discovery, yielding more successfully and personified regenerative treatments.
The large search space and the challenge of accurately simulating quantum-level molecular interactions are the fundamental causes of the delayed, complicated, and costly process of discovering new medications. The effectiveness of conventional computational techniques, including molecular docking and molecular dynamics, to assess molecular characteristics and provide highly accurate drug candidate predictions is constrained. This paper presents a Quantum-Assisted Drug Discovery Simulation framework that combines cutting-edge quantum computing algorithms, specifically the Quantum Approximate Optimization Algorithm (QAOA) and the Variational Quantum Eigensolver (VQE), with traditional molecular docking tools like RDKit and AutoDock. The system uses these quantum algorithms to perform very accurate Quantum Refinement on the most potential therapeutic protein poses found by classical identification. This hybrid approach seeks to optimize drug-protein interactions more quickly, speed up early-stage drug discovery, and create opportunities for less costly, more accurate medical research, even though a combination of quantum and classical calculations allows more accurate prediction of molecular energies and binding affinities.
By facilitating quicker and more precise analysis of intricate biological data, the union of quantum computing and Artificial Intelligence (AI) may transform genomic medicine and drug discovery altogether. The study suggests a model for artificial intelligence with quantum-enhanced acceleration based on hybrid quantum-classical models in order to speed up drug discovery and customize therapies. It utilizes deep learning models and Quantum Machine Learning (QML) techniques to analyze patient-specific data, protein structures, and genetic sequences. Large genomic and clinical data sets are processed by conventional deep learning models, while the quantum component carries out efficient data encoding and optimization processes. As compared to other traditional AI-based approaches, the proposed model performs a 30% improved drug target identification when evaluated against more than 1,000 genetic sequences and related clinical outcomes. The hybrid model was as accurate as 98.4% in its prediction and was more accurate than the conventional AI techniques including random forests (accuracy: 91.3%) and gradient boosting machines (accuracy: 93.7%). The methodology also produced an F1-score of 0.95 with accuracy and recall scores of 96.1% and 94.7%, respectively. These results demonstrate how quantum-enhanced AI can reduce the time for computation and improve the accuracy of genomic data analysis, driving significant progress toward personalized therapy and drug development.
Quantum AI, the integration of quantum computing and artificial intelligence, is revolutionizing drug design by addressing the limitations of traditional pharmaceutical development. This review explores its transformative potential in enhancing molecular simulations, structure-based, target-based, and ligand-based drug discovery, and personalized medicine. Quantum computing leverages principles like superposition, entanglement, and interference to perform complex calculations exponentially faster than classical systems, enabling precise modeling of molecular interactions. Algorithms such as the Variational Quantum Eigensolver (VQE) and Quantum Phase Estimation (QPE) outperform classical methods like Density Functional Theory (DFT) in accuracy and efficiency, facilitating the identification of promising drug candidates and optimizing their pharmacokinetic properties. Quantum AI also enhances personalized medicine by analyzing vast genomic datasets to tailor treatments, improving efficacy and minimizing adverse effects. Despite challenges, including noisy intermediate-scale quantum (NISQ) device limitations and the need for advanced error correction, ongoing research and interdisciplinary collaboration are driving progress. Quantum AI promises to reduce development costs, accelerate drug discovery, and democratize access to life-saving medications. By enabling simulation-based discovery and expanding drug-candidate libraries to include peptides and antibodies, it paves the way for breakthroughs in treating complex diseases. This review underscores the need for continued investment in quantum technology to fully harness its potential, positioning the pharmaceutical industry for a future where drug development is faster, more precise, and patient-centric, ultimately improving global healthcare outcomes.
The traditional drug discovery process is slow, resource-intensive, and often unsuccessful. This is mainly because regular computers find it hard to accurately model complex molecular interactions at the quantum level. This abstract suggests that Quantum Computing (QC) could change the game. It uses the principles of superposition and entanglement to transform pharmaceutical research. QC will provide a significant increase in computing power for quantum chemistry simulations. This will help researchers model the electronic structure of molecules and their exact behavior, including protein folding, binding affinities, and off-target effects, with great accuracy and speed. Algorithms like the Variational Quantum Eigensolver (VQE) are expected to uncover insights into drug-target interactions that we cannot currently obtain. This will greatly reduce the need for costly and lengthy physical experiments. Additionally, QC can improve virtual screening and support next-generation Quantum AI for faster analysis of genomic data and better optimization of drug candidates. Though the technology is still in its early stages, using QC could notably shorten development timelines and lower costs. This will enable the discovery of more targeted and effective drugs, leading to significant progress in treating complex diseases and a new era of precise, personalized medicine. The shift will require ongoing investment in reliable quantum hardware and specialized quantum algorithms.